Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. Shares of Corcept surged about 84 ...
Faulty lipid regulation in CLL patients impairs T-cell function, affecting treatment outcomes and resistance to current therapies ... T cell therapy efficacy. Modulating cholesterol metabolism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback